홀로직(HOLX) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

🏛️

거래 정지 중인 종목 2026-06-04 이후 거래가 정지되었습니다. 재개될 수 있으며, 표시된 시세는 마지막 거래일 기준입니다.

HOLX

Hologic, Inc

$76.01

+0.00 +0.00%

홀로직(HOLX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$17.0B

미드캡

P/E

31.5

적정 수준

배당수익률

없음

52주 위치

100%

저점 +46% · 고점 -0%

애널리스트

보유

Fundamental health

vs. Medical Instruments & Supplies

수익성

Top 37%

성장

Top 87%

밸류에이션

Top 57%

재무 안정

Top 38%

Index ⓘ	-	P/E ⓘ	31.54	EPS (ttm) ⓘ	2.41	Insider Own ⓘ	1.55%	Shs Outstand ⓘ	223.1M	Perf Week ⓘ	-
Market Cap ⓘ	16.97B	Forward P/E ⓘ	15.9	EPS next Y ⓘ	8.02%	Insider Trans ⓘ	-0.21%	Shs Float ⓘ	219.8M	Perf Month ⓘ	1.28%
Enterprise Value ⓘ	17.12B	PEG ⓘ	2.52	EPS next Q ⓘ	1.05	Inst Own ⓘ	96.49%	Short Float ⓘ	3.73%	Perf Quarter ⓘ	1.13%
Income ⓘ	0.54B	P/S ⓘ	4.11	EPS this Y ⓘ	3.87%	Inst Trans ⓘ	-	Short Ratio ⓘ	1.85	Perf Half Y ⓘ	15.31%
Sales ⓘ	4.13B	P/B ⓘ	3.23	EPS next 5Y ⓘ	6.32%	ROA ⓘ	6.07%	Short Interest ⓘ	8.20M	Perf YTD ⓘ	2.04%
Book/sh ⓘ	23.51	P/C ⓘ	7.18	EPS past 3/5Y ⓘ	-21.45% -10.02%	ROE ⓘ	10.86%	52W High ⓘ	-0.08% ($76.07)	Perf Year ⓘ	24.89%
Cash/sh ⓘ	10.59	P/FCF ⓘ	17.73	Sales past 3/5Y ⓘ	-5.53% 1.66%	ROIC ⓘ	7.01%	52W Low ⓘ	46.45% ($51.90)	Perf 3Y ⓘ	-8.27%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	13.57	EPS Y/Y TTM ⓘ	-23.89%	Gross Margin ⓘ	55.62%	Volatility(W/M) ⓘ	0.22% 0.27%	Perf 5Y ⓘ	1.73%
Dividend TTM ⓘ	-	EV/Sales ⓘ	4.15	Sales Y/Y TTM ⓘ	2.17%	Oper. Margin ⓘ	23.66%	ATR (14) ⓘ	0.23	Perf 10Y ⓘ	112.62%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	3.32	EPS Q/Q ⓘ	-8.44%	Profit Margin ⓘ	13.18%	RSI (14) ⓘ	68.74	Recom ⓘ	3.25
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	4.04	Sales Q/Q ⓘ	2.54%	SMA20 ⓘ	0.71% ($75.47)	Beta ⓘ	0.73	Target Price ⓘ	$76
Payout ⓘ	-	Debt/Eq ⓘ	0.48	Earnings ⓘ	2026/1/29	SMA50 ⓘ	0.96% ($75.29)	Rel Volume ⓘ	0	Prev Close ⓘ	$76.01
Employees ⓘ	7070	LT Debt/Eq ⓘ	0.48	EPS/Sales Surpr. ⓘ	-5.08% -2.2%	SMA200 ⓘ	6.64% ($71.28)	Avg Volume(3M) ⓘ	4.44M	Price ⓘ	$76.01
IPO ⓘ	1990/3/1	Option/Short ⓘ	Yes/No			Trades ⓘ	0	Volume ⓘ	-	Change ⓘ	-

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Hologic, Inc (HOLX) Investment Analysis

What kind of company is Hologic, Inc?

홀로직(HOLX) 방어주

Healthcare · Medical Instruments & Supplies

#677 by Market Cap — Mid-Cap

🩺 This company is a medical device and diagnostics company focused on women's health. It supplies medical devices and diagnostic solutions specialized in women's health, including breast imaging diagnostics (mammography), molecular diagnostics, gynecological surgical instruments, and bone density testing. It is one of the leading companies in the women's health medical device sector.

Learn more about Hologic, Inc →

Market Cap

$17.0B

Approx. KRW 23.2 trillion

⚖️ 6% of Samsung Electronics

Market Cap Rank677

Employees7,070people

IPO1990/03/01

Current Price$76.01 ≈ 104,134원

NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 1월 29일 (목) · 장 마감 후 EPS -5.1% 매출 -2.2%

Is it profitable?

Financial health solid

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

23.7%

✓ 우수

My positionTop 25%

Low range Average High range

Medical Instruments & Supplies Median 5.5% · Top 15%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

13.2%

✓ 우수

My positionTop 25%

Low range Average High range

Medical Instruments & Supplies Median -5.3% · Top 21%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

55.6%

✓ 양호

My positionMid-range

Low range Average High range

Medical Instruments & Supplies Median 48.6% · Top 35%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

10.9%

✓ 평균

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 11.9% · Bottom 47%

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

6.1%

✓ 양호

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 5.1% · Top 45%

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

7.0%

✓ 평균

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 7.4% · Bottom 48%

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.48

✓ Healthy debt

My positionMid-range

Low range Average High range

Medical Instruments & Supplies Median 0.26

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

4.04

✓ 양호

My positionMid-range

Low range Average High range

Medical Instruments & Supplies Median 2.34

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

3.32

✓ 양호

My positionMid-range

Low range Average High range

Medical Instruments & Supplies Median 1.97

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$76.00

현재가 대비 -0.0%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

15.90배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

2.52

고평가

💡 PEG > 2 — 성장 대비 비싼 편

내년 EPS 예상 성장률

+8.0%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+6.3%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-5.4%

평균 서프라이즈

2026.01.29

하회

실적 $1.04 · 예상 $1.10 -5.4%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Concerns

Growth is lagging the industry average

Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+3.9%

평균

My positionMid-range

Low range Average High range

방어주 대형주 Median 9.6% · Bottom 26%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+8.0%

부진

My positionBottom 25%

Low range Average High range

방어주 대형주 Median 10.8% · Bottom 18%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+6.3%

부진

My positionBottom 25%

Low range Average High range

방어주 대형주 Median 9.8% · Bottom 13%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

-21.4%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 대형주 Median 4.7% · Bottom tier

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

-10.0%

매우 부진

My positionBottom 5%

Low range Average High range

방어주 대형주 Median 4.1% · Bottom tier

Past 5-Year Revenue

How much revenue grew over the past 5 years

+1.7%

부진

My positionBottom 25%

Low range Average High range

방어주 대형주 Median 6.7% · Bottom 13%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+2.5%

부진

My positionBottom 25%

Low range Average High range

방어주 대형주 Median 8.4% · Bottom 23%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -67%p below the market

HOLX +1.7% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-66.6%p

Significantly behind the market

vs Health Care (XLV)

-22.8%p

behind the sector average

1-year basis

vs S&P 500

+8.9%p

slightly ahead of the market

vs Health Care (XLV)

+5.2%p

slightly ahead of the sector average

Current position within 52-week range

Low (-46.5%p) High (-0.1%p)

Current price is 46.5% above the 52-week low and 0.1% below the 52-week high

Recent risk (last 60 trading days)

Max drawdown

-0.9%

Annualized volatility

2.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 68-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟡

Current diagnosis · 2026-04-17

Squeeze — volatility contraction, breakout imminent

Band width narrowed to 1.2%. Big move may be near. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢

Current diagnosis · 2026-04-17

Bullish momentum holding

MACD 0.175 > Signal 0.168 in positive zone + Hist positive (+0.007). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-04-17

Bullish zone

RSI 68.7 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 89.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Cash Flow, In line with peers on Vs. Assets·Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Mid-range

🧾 Vs. Sales Mid-range

💧 Vs. Cash Flow Cheap

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

31.54x

✓ Cheap

My positionMid-range

Low range Average High range

Medical Instruments & Supplies median 35.22x · Around the industry average

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

15.90x

✓ Cheap

My positionMid-range

Low range Average High range

Medical Instruments & Supplies median 18.44x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

3.23x

✓ Fair

My positionMid-range

Low range Average High range

Medical Instruments & Supplies median 2.71x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

4.11x

✓ Fair

My positionMid-range

Low range Average High range

Medical Instruments & Supplies median 2.92x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

13.57x

✓ Cheap

My positionMid-range

Low range Average High range

Medical Instruments & Supplies median 14.76x · Around the industry average

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

17.73x

✓ Very cheap

My positionTop 25%

Low range Average High range

Medical Instruments & Supplies median 25.16x · Top 18% — relatively cheap within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$76.00 vs. current price -0.0%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Medical Instruments & Supplies

Who owns it?

Ownership flow shows some pressure

Insider modest net selling -0.2% · Short interest light 3.7% · Short interest up +2.0pp over last 60d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-0.2%

Insiders net selling

🏦 Institutions (funds & investors)

No trading data for Institutions

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 96.5%

Institution-led, stable structure

Healthcare 대형주 Median 91.9%

🧑‍💼 Insiders 1.6%

Typical level

Healthcare 대형주 Median 0.8%

👤 Retail investors (estimated) 2.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

3.7%

Low — limited short-side pressure

Healthcare 대형주 Median 3.6%

Past 60 days 📈 +2.0%p increase

Short interest days to cover

1.9 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 223.1M주

Float (tradable shares) 219.8M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 60 days.

ETFs holding HOLX

ETFs with the highest weightings · 10 total shown

EVNT

AltShares Event-Driven ETF

4.64%

$13M

ARB

AltShares Merger Arbitrage ETF

2.82%

$102M

MDEV

First Trust Indxx Medical Devices ETF

iShares U.S. Medical Devices ETF

2.28%

$3.0B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
HOLX This Stock	$17.0B	31.5 ▼	3.2 ▼	10.86% ▲	-	+0.0%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 홀로직(HOLX)?

홀로직(HOLX) belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.

What is the market cap of HOLX?

The market cap of HOLX is approximately $17.0B, ranking 677 within its sector.

What is the P/E ratio of HOLX?

HOLX has a P/E ratio of approximately 31.5x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for HOLX?

HOLX has recorded a 52-week high of $76.07 and a low of $51.90.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.